Organon & Co | OGN - Equity Capital And Reserves


Organon & Co reported $1.19B in Equity Capital and Reserves for its fiscal quarter ending in September of 2026.





Equity Capital And Reserves Change Date
Bristol-Myers Squibb USD 23.4B 1.08B Sep/2026
Celltrion KRW 449.2B 14.38B Jun/2026
Cspc Pharmaceutical CNY 33.18B 71.46M Dec/2025
Deva Holding AS TRY 5.79B 604.07M Sep/2023
Dianthus Therapeutics USD 1.24B 69.4M Sep/2026
Divis Laboratories Ltd INR 167.61B 13.48B Mar/2026
Gilead Sciences USD 13.04B 1.3B Sep/2026
Glaxosmithkline GBP 18.36B 940M Sep/2026
Kangmei Pharma CNY 7.83B 524.96M Jun/2026
Knight Therapeutics CAD 767.27M 480K Dec/2025
Laboratorios Farma EUR 539.39M 22.74M Dec/2023
Malin Corporation EUR 193.2M 75M Dec/2024
Medical Developments International AUD 54.77M 335K Dec/2025
Merck USD 44.89B 2.96B Sep/2026
Neuren Pharmaceuticals AUD 338.45M 15.18M Dec/2025
Novartis USD 37.56B 1.36B Sep/2026
Organigram Holdings CAD 485.46M 113.65M Jun/2026
Organon & Co USD 1.19B 187M Sep/2026
Ovoca Bio EUR 780K 485K Dec/2025
Pharma Mar EUR 237M 13.77M Sep/2026
Qiagen NV USD 3.36B 26.03M Jun/2026
Sartorius EUR 2.93B 110.1M Sep/2026
Sino Biopharmaceutical CNY 34B 1.48B Jun/2025
Tilray USD 1.58B 39.08M Sep/2025
Zealand Pharma A/S 14.47B 361.61M Mar/2026